Methods: Adult treatment-naïve patients were randomly assigned to DCV/peg-alfa-2a/RBV for MAPK Inhibitor Library cell assay 12 or 16 weeks or placebo/peg-alfa-2a/RBV for 24 weeks. DCV/peg-alfa-2a/RBV recipients without protocol-defined response (PDR; HCV RNA

(N = 50), DCV 16-week (N = 50) and placebo (N = 51) arms; more patients with GT3 (18/80, 22.5%) than GT2 (1/71, 1.4%) ubiquitin-Proteasome system were cirrhotic. 78%-88% of DCV recipients achieved PDR. SVR24 rates were higher in GT2 than GT3 with all regimens;

within each genotype, SVR24 rates were similar in DCV arms and higher than placebo/peg-alfa-2a/RBV. In GT2, the SVR24 rate in each DCV arm was 83%; in the placebo/peg-alfa-2a/RBV arm, the SVR24 rate was 63%. In GT3, the SVR24 rate in the 12-week and 16-week DCV arms were 69% and 67%, respectively; in the placebo/peg-alfa-2a/RBV arm, the SVR24 rate was 59%. In DCV arms, one GT2 and 12 GT3 patients relapsed. In GT3, relapse was higher among cirrhotics (3/7, 43%) than non-cirrhotics (3/19, 16%) in the 12-week arm but similar in the 16-week arm (1/4, 25% vs 5/20, 25%). There were 7 on-treatment serious AEs (DCV, 4; placebo, 3); no deaths. AEs were typical of those associated with peg-alfa/RBV. Conclusion: Shorter treatment duration (12 or 16 weeks) with DCV/peg-alfa-2a/RBV demonstrated higher SVR rates than 24 weeks of peg-alfa-2a/RBV in patients with GT2 or GT3 infection, with higher SVR rates in GT2 with all regimens.

These results support further evaluation of DCV-containing regimens for different HCV genotypes. Funding disclosures: This BCKDHB study was funded by Bristol-Myers Squibb (BMS). Editorial support was provided by Articulate Science and BMS and funded by BMS. Resistance analyses were contributed by Fiona McPhee of BMS. T ASSELAH,1 S ZEUZEM,2 V SORIANO,3 J-P BRONOWICKI,4 AW LOHSE,5 B MÜLLHAUPT,6 M SCHUCHMANN,7 M BOURLIERE,8 M BUTI,9 S ROBERTS,10 ED GANE,11 J STERN,12 P BAUM,13 J-P GALLIVAN,14 W BÖCHER,14 F MENSA12 1Hôpital Beaujon, Clichy, France, 2Klinikum der J. W.